Rationally designed multitarget anticancer agents

Current Medicinal Chemistry

Volumn 20, Issue 13, 2013, Pages 1694-1714

  Chen, Zhuo ^a   Han, Le ^a   Xu, Minghao ^a   Xu, Yufang ^a   Qian, Xuhong ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemotherapy; Multitarget; Naphthalimide; Pharmacophore combination; Quinazoline; Tumor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; AL 232; AL 414; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BELINOSTAT; BJ 2000; CARMUSTINE; CETRORELIX; CUDC 101; ENTINOSTAT; ERLOTINIB; FD 110; FD 137; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; JDA 58; LAPATINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; NAPHTHALIMIDE; NSC 741282; PHENYLAMINOPYRIMIDINE; QUINAZOLINE DERIVATIVE; SB 162; SB 166; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZR 2002; ZR 2003;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FREE SYSTEM; CELL LINE; CELL PROLIFERATION; DNA ALKYLATION; DNA DAMAGE; DNA REPLICATION; DRUG APPROVAL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; EXCISION REPAIR; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; NONHUMAN; PHARMACOPHORE; PROTEIN PHOSPHORYLATION; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NAPHTHALIMIDES; NEOPLASMS; QUINAZOLINES;

EID: 84877941156     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320130009     Document Type: Article

References (115)

1. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48 (21), 6523-6543.
2. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 2006, 16 (1), 127-136.
3. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9 (15), 641-651.
4. Hopkins, A. L., Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol., 2008, 4 (11), 682-690.
5. Borisy, A. A.; Elliott, P. J.; Hurst, N. W.; Lee, M. S.; Lehar, J.; Price, E. R.; Serbedzija, G.; Zimmermann, G. R.; Foley, M. A.; Stockwell, B. R.; Keith, C. T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U.S.A., 2003, 100 (13), 7977-7982.
6. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12 (1-2), 34-42.
7. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multitarget drugs: The network approach might help drug design. Trends Pharmacol. Sci., 2005, 26 (4), 178-182.
8. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer, 2002, 2 (3), 188-200.
9. Sawyers, C. Targeted cancer therapy. Nature, 2004, 432 (7015), 294-297.
10. Kummar, S.; Chen, H. X.; Wright, J.; Holbeck, S.; Millin, M. D.; Tomaszewski, J.; Zweibel, J.; Collins, J.; Doroshow, J. H. Utilizing targeted cancer therapeutic agents in combination: Novel approaches and urgent requirements. Nat. Rev. Drug Discov., 2010, 9 (11), 843-856.
11. Broxterman, H. J.; Georgopapadakou, N. H. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist. Update, 2005, 8 (4), 183-197.
12. Wei, D. G.; Jiang, X. L.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J. F.; Lai, L. H. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem., 2008, 51 (24), 7882-7888.
13. Dancey, J. E.; Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 2006, 5 (8), 649-659.
14. Morphy, R.; Rankovic, Z. Designing multiple ligands-Medicinal chemistry strategies and challenges. Curr. Pharm. Design, 2009, 15 (6), 587-600.
15. Korcsmaros, T.; Szalay, M. S.; Csaba, B.; Kovacs, I. A.; Csermely, P. How to design multi-target drugs: Target search options in cellular networks. Expert Opin. Drug Discov., 2007, 2 (6), 799-808.
16. Lee, K. W.; Bode, A. M.; Dong, Z. G. Molecular targets of phytochemicals for cancer prevention. Nat. Rev. Cancer, 2011, 11 (3), 211-218.
17. Lee, K. M.; Lee, K. W.; Byun, S.; Jung, S. K.; Seo, S. K.; Heo, Y. S.; Bode, A. M.; Lee, H. J.; Dong, Z. G. 5-Deoxykaempferol plays a potential therapeutic role by targeting multiple signaling pathways in skin cancer. Cancer Prev. Res., 2010, 3 (4), 454-465.
18. Solomon, V. R.; Lee, H. Quinoline as a privileged scaffold in cancer drug discovery. Curr. Med. Chem., 2011, 18 (10), 1488-1508.
19. Belmont, P.; Bosson, J.; Godet, T.; Tiano, M. Acridine and acridone derivatives, anticancer properties and synthetic methods: Where are we now? Anticancer Agents Med. Chem., 2007, 7 (2), 139-169.
20. Teiten, M. H.; Eifes, S.; Dicato, M.; Diederich, M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel), 2010, 2 (1), 128-162.
21. Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem., 2006, 49 (16), 4961-4970.
22. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev., 1997, 23 (1-3), 3-25.
23. O'Boyle, N. M.; Meegan, M. J. Designed multiple ligands for cancer therapy. Curr. Med. Chem., 2011, 18 (31), 4722-4737.
24. Viegas-Junior, C.; Danuello, A.; Bolzani, V. D.; Barreir, E. J.; Fraga, C. A. M. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem., 2007, 14 (17), 1829-1852.
25. Gediya, L. K.; Njar, V. C. O. Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin. Drug Discov., 2009, 4 (11), 1099-1111.
26. Keely, N. O.; Meegan, M. J. Targeting tumors using estrogen receptor ligand conjugates. Curr. Cancer Drug Tar., 2009, 9 (3), 370-380.
27. Matheson, S. L.; McNamee, J.; Jean-Claude, B. J. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumor targeting strategy. J. Pharmacol. Exp. Ther., 2001, 296 (3), 832-840.
28. Rachid, Z.; Brahimi, F.; Katsoulas, A.; Teoh, N.; Jean-Claude, B. J. The combi-targeting concept: Chemical dissection of the dual targeting properties of a series of "combi-triazenes". J. Med. Chem., 2003, 46 (20), 4313-4321.
29. Convery, E.; Shin, E. K.; Ding, Q.; Wang, W.; Douglas, P.; Davis, L. S.; Nickoloff, J. A.; Lees-Miller, S. P.; Meek, K. Inhibition of homologous recombination by variants of the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs). Proc. Natl. Acad. Sci. U.S.A., 2005, 102 (5), 1345-1350.
30. Matheson, S. L.; McNamee, J. P.; Jean-Claude, B. J. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother. Pharm., 2003, 51 (1), 11-20.
31. Matheson, S. L.; Mzengeza, S.; Jean-Claude, B. J. Synthesis of 1-[4-(m-tolyl)amino-6-quinazolinyl]3-[C-14]-methyl triazene: A radiolabeled probe for the combi-targeting concept. J. Labelled Compd. Rad., 2003, 46 (8), 729-735.
32. Matheson, S. L.; Brahimi, F.; Jean-Claude, B. J. The combitargeting concept: Intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem. Pharmacol., 2004, 67 (6), 1131-1138.
33. Matheson, S. L.; McNamee, J. P.; Wang, T. Q.; Alaoui-Jamali, M. A.; Tari, A. M.; Jean-Claude, B. J. The combi-targeting concept: Dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J. Pharmacol. Exp. Ther., 2004, 311 (3), 1163-1170.
34. Brahimi, F.; Matheson, S. L.; Dudouit, F.; McNamee, J. P.; Tari, A. M.; Jean-Claude, B. J. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for Combi-Targeting postulates. J. Pharmacol. Exp. Ther., 2002, 303 (1), 238-246.
35. MacPhee, M.; Rachid, Z.; Todorova, M.; Qiu, Q. Y.; Belinsky, G.; Jean-Claude, B. J. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest. New Drug, 2011, 29 (5), 833-845.
36. Banerjee, R.; Rachid, Z.; McNamee, J.; Jean-Claude, B. J. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: A novel tumor targeting concept. J. Med. Chem., 2003, 46 (25), 5546-5551.
37. Banerjee, R.; Rachid, Z.; Qiu, Q.; McNamee, J. P.; Tari, A. M.; Jean-Claude, B. J. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br. J. Cancer, 2004, 91 (6), 1066-1073.
38. Banerjee, R.; Huang, Y.; McNamee, J. P.; Todorova, M.; Jean-Claude, B. J. The combi-targeting concept: Selective targeting of the epidermal growth factor receptor-and Her2-expressing cancer cells by the complex combi-molecule RB24. J. Pharmacol. Exp. Ther., 2010, 334 (1), 9-20.
39. Banerjee, R.; Huang, Y.; Qiu, Q. Y.; Mcnamee, J. P.; Belinsky, G.; Jean-Claude, B. J. The combi-targeting concept: Mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle. Cell. Signal., 2011, 23 (4), 630-640.
40. Rachid, Z.; MacPhee, M.; Williams, C.; Todorova, M.; Jean-Claude, B. J. Design and synthesis of new stabilized combitriazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorg. Med. Chem. Lett., 2009, 19 (18), 5505-5509.
41. Huang, Y.; Rachid, Z.; Jean-Claude, B. J. MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1. Mol. Cancer Res., 2011, 9 (3), 320-331.
42. Brahimi, F.; Rachid, Z.; McNamee, J. P.; Alaoui-Jamali, M. A.; Tari, A. M.; Jean-Claude, B. J. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: Evidence for enhancement of potency. Biochem. Pharmacol., 2005, 70 (4), 511-519.
43. Merayo, N.; Rachid, Z.; Qiu, Q.; Brahimi, F.; Jean-Claude, B. J. The combi-targeting concept: Evidence for the formation of a novel inhibitor in vivo. Anti-Cancer Drug, 2006, 17 (2), 165-171.
44. Heravi, M.; Rachid, Z.; Goudarzi, A.; Schlisser, A.; Jean-Claude, B. J.; Radzioch, D.; Muanza, T. M. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anti-Cancer Drug, 2009, 20 (8), 659-667.
45. Rachid, Z.; Brahimi, F.; Qiu, Q.; Williams, C.; Hartley, J. M.; Hartley, J. A.; Jean-Claude, B. J. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure-activity relationship. J. Med. Chem., 2007, 50 (11), 2605-2608.
46. Qiu, Q. Y.; Dudouit, F.; Matheson, S. L.; Brahimi, F.; Banerjee, R.; McNamee, J. P.; Jean-Claude, B. J. The combi-targeting concept: A novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother. Pharm., 2003, 51 (1), 1-10.
47. Qiu, Q. Y.; Dudouit, F.; Banerjee, R.; McNamee, J. P.; Jean-Claude, B. J. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate, 2004, 59 (1), 13-21.
48. Domarkas, J.; Dudouit, F.; Williams, C.; Qiu, Q. Y.; Banerjee, R.; Brahimi, F.; Jean-Claude, B. J. The combi-targeting concept: Synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J. Med. Chem., 2006, 49 (12), 3544-3552.
49. Qiu, Q. Y.; Domarkas, J.; Banerjee, R.; Merayo, N.; Brahimi, F.; McNamee, J. P.; Gibbs, B. F.; Jean-Claude, B. J. The combitargeting concept: In vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin. Cancer Res., 2007, 13 (1), 331-340.
50. Larroque-Lombard, A. L.; Todorova, M.; Qiu, Q. Y.; Jean-Claude, B. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK. Chem. Biol. Drug Des., 2011, 77 (5), 309-318.
51. Rachid, Z.; Brahimi, F.; Domarkas, J.; Jean-Claude, B. J. Synthesis of half-mustard combi-molecules with fluorescence properties: Correlation with EGFR status. Bioorg. Med. Chem. Lett., 2005, 15 (4), 1135-1138.
52. Brahimi, F.; Rachid, Z.; Qiu, Q. Y.; McNamee, J. P.; Li, Y. J.; Tari, A. M.; Jean-Claude, B. J. Multiple mechanisms of action of ZR2002 in human breast cancer cells: A novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int. J. Cancer, 2004, 112 (3), 484-491.
53. Golabi, N.; Brahimi, F.; Huang, Y.; Rachid, Z.; Qiu, Q. Q.; Larroque-Lombard, A. L.; Jean-Claude, B. J. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity. J. Pharm. Biomed., 2011, 56 (3), 592-599.
54. Qiu, Q. Y.; Domarkas, J.; Banerjee, R.; Katsoulas, A.; McNamee, J. P.; Jean-Claude, B. J. Type II combi-molecules: Design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anti-Cancer Drug, 2007, 18 (2), 171-177.
55. Barchechath, S.; Williams, C.; Saade, K.; Lauwagie, S.; Jean-Claude, B. Rational design of multitargeted tyrosine kinase inhibitors: A novel approach. Chem. Biol. Drug Des., 2009, 73 (4), 380-387.
56. Antonello, A.; Tarozzi, A.; Morroni, F.; Cavalli, A.; Rosini, M.; Hrelia, P.; Bolognesi, M. L.; Melchiorre, C. Multitarget-directed drug design strategy: A novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. J. Med. Chem., 2006, 49 (23), 6642-6645.
57. Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth gactor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J. Med. Chem., 2010, 53 (24), 8546-8555.
58. Cai, X.; Zhai, H. X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C. J.; Bao, R. D.; Qian, C. G. Discovery of 7-(4-(3-ethynylpheny lamino)α7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53 (5), 2000-2009.
59. Lai, C. J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D. G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G. X.; DellaRocca, S.; Zhai, H. X.; Cai, X.; Munger, W. E.; Keegan, M.; Pepicelli, C. V.; Qian, C. G. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res., 2010, 70 (9), 3647-3656.
60. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol., 2005, 23 (5), 1011-1027.
61. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U.S.A., 2005, 102 (21), 7665-7670.
62. Wissner, A.; Floyd, M. B.; Johnson, B. D.; Fraser, H.; Ingalls, C.; Nittoli, T.; Dushin, R. G.; Discafani, C.; Nilakantan, R.; Marini, J.; Ravi, M.; Cheung, K.; Tan, X.; Musto, S.; Annable, T.; Siegel, M. M.; Loganzo, F. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. J. Med. Chem., 2005, 48 (24), 7560-7581.
63. Wissner, A.; Fraser, H. L.; Ingalls, C. L.; Dushin, R. G.; Floyd, M. B.; Cheung, K.; Nittoli, T.; Ravi, M. R.; Tan, X. Z.; Loganzo, F. Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg. Med. Chem., 2007, 15 (11), 3635-3648.
64. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B. Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett., 1997, 7 (2), 187-192.
65. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B.; Traxler, P. Phenylamino-pyrimidine (PAP)-derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett., 1996, 6 (11), 1221-1226.
66. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Mohammed, A.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7 (2), 129-141.
67. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl. J. Med., 2006, 354 (24), 2531-2541.
68. Lu, S.; Luo, Q.; Hao, X.; Li, X. C.; Ji, L. Y.; Zheng, W.; Wang, F. Y. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21 (23), 6964-6968.
69. Katsoulas, A.; Rachid, Z.; Brahimi, F.; McNamee, J.; Jean-Claude, B. J. Engineering 3-alkyltriazenes to block bcr-abl kinase: A novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leukemia Res., 2005, 29 (6), 693-700.
70. Katsoulas, A.; Rachid, Z.; Brahimi, F.; McNamee, J.; Jean-Claude, B. J. Cytokinetics and mechanism of action of AKO4: A novel nitrogen mustard targeted to bcr-abl. Leukemia Res., 2005, 29 (5), 565-572.
71. Rachid, Z.; Katsoulas, A.; Williams, C.; Larroque, A. L.; McNamee, J.; Jean-Claude, B. J. Optimization of novel combimolecules: Identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg. Med. Chem. Lett., 2007, 17 (15), 4248-4253.
72. Katsoulas, A.; Rachid, Z.; McNamee, J. P.; Williams, C.; Jean-Claude, B. J. Combi-targeting concept: An optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Mol. Cancer Ther., 2008, 7 (5), 1033-1043.
73. Amrein, L.; Rachid, Z.; Jean-Claude, B.; Soulieres, D.; Aloyz, R.; Panasci, L. ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro. Leukemia, 2011, 25 (9), 1512-1516.
74. Nimmanapalli, R.; Fuino, L.; Bali, P.; Gasparetto, M.; Glozak, M.; Tao, J. G.; Moscinski, L.; Smith, C.; Wu, J.; Jove, R.; Atadja, P.; Bhalla, K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res., 2003, 63 (16), 5126-5135.
75. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase-and tyrosine kinase-inhibitors: A series of imatinib hybrids as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-R beta, and histone deacetylases. J. Med. Chem., 2009, 52 (8), 2265-2279.
76. Uecker, A.; Sicker, M.; Beckers, T.; Mahboobi, S.; Hagerstrand, D.; Ostman, A.; Bohmer, F. D. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. Anti-Cancer Drug, 2010, 21 (8), 759-765.
77. Srivastava, S. K.; Kumar, V.; Agarwal, S. K.; Mukherjee, R.; Burman, A. C. Synthesis of quinazolines as tyrosine kinase inhibitors. Anti-Cancer Agent Med. Chem., 2009, 9 (3), 246-275.
78. Marzaro, G.; Guiotto, A.; Chilin, A. Quinazoline derivatives as potential anticancer agents: A patent review (2007-2010). Expert Opin. Ther. Pat., 2012, 22 (3), 223-252.
79. Bianco, C.; Giovannetti, E.; Ciardiello, F.; Mey, V.; Nannizzi, S.; Tortora, G.; Troiani, T.; Pasqualetti, F.; Eckhardt, G.; de Liguoro, M.; Ricciardi, S.; Del Tacca, M.; Raben, D.; Cionini, L.; Danesi, R. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin. Cancer Res., 2006, 12 (23), 7099-7107.
80. Ciardiello, F.; Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, D.; De Vita, F.; De Placido, S.; Bianco, A. R.; Tortora, G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res., 2004, 10 (2), 784-793.
81. Garofalo, A.; Goossens, L.; Lemoine, A.; Ravez, S.; Six, P.; Howsam, M.; Farce, A.; Depreux, P. 4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl carbamic acid esters: A novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors. MedChemComm, 2011, 2 (1), 65-72.
82. Garofalo, A.; Goossens, L.; Lemoine, A.; Farce, A.; Arlot, Y.; Depreux, P. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer. J. Enzyme Inhib. Med. Chem., 2010, 25 (2), 158-171.
83. Motzer, R. J.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Figlin, R. A.; Ginsberg, M. S.; Kim, S. T.; Baum, C. M.; DePrimo, S. E.; Li, J. Z.; Bello, C. L.; Theuer, C. P.; George, D. J.; Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24 (1), 16-24.
84. Ple, P. A.; Jung, F.; Ashton, S.; Hennequin, L.; Laine, R.; Morgentin, R.; Pasquet, G.; Taylor, S. Discovery of AZD2932, a new quinazoline ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg. Med. Chem. Lett., 2012, 22, 262-266.
85. Mortlock, A. A.; Foote, K. M.; Heron, N. M.; Jung, F. H.; Pasquet, G.; Lohmann, J. J. M.; Warin, N.; Renaud, F.; De Savi, C.; Roberts, N. J.; Johnson, T.; Dousson, C. B.; Hill, G. B.; Perkins, D.; Hatter, G.; Wilkinson, R. W.; Wedge, S. R.; Heaton, S. P.; Odedra, R.; Keen, N. J.; Crafter, C.; Brown, E.; Thompson, K.; Brightwell, S.; Khatri, L.; Brady, M. C.; Kearney, S.; McKillop, D.; Rhead, S.; Parry, T.; Green, S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J. Med. Chem., 2007, 50 (9), 2213-2224.
86. Tasler, S.; Muller, O.; Wieber, T.; Herz, T.; Krauss, R.; Totzke, F.; Kubbutat, M. H. G.; Schachtele, C. N-substituted 2 '-(aminoaryl)benzothiazoles as kinase inhibitors: Hit identification and scaffold hopping. Bioorg. Med. Chem. Lett., 2009, 19 (5), 1349-1356.
87. Tasler, S.; Muller, O.; Wieber, T.; Herz, T.; Pegoraro, S.; Saeb, W.; Lang, M.; Krauss, R.; Totzke, F.; Zirrgiebel, U.; Ehlert, J. E.; Kubbutat, M. H. G.; Schachtele, C. Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization. Bioorg. Med. Chem., 2009, 17 (18), 6728-6737.
88. Mott, B. T.; Tanega, C.; Shen, M.; Maloney, D. J.; Shinn, P.; Leister, W.; Marugan, J. J.; Inglese, J.; Austin, C. P.; Misteli, T.; Auld, D. S.; Thomas, C. J. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg. Med. Chem. Lett., 2009, 19 (23), 6700-6705.
89. Rosenthal, A. S.; Tanega, C.; Shen, M.; Mott, B. T.; Bougie, J. M.; Nguyen, D. T.; Misteli, T.; Auld, D. S.; Maloney, D. J.; Thomas, C. J. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosinephosphorylation-regulated kinases (Dyrk). Bioorg. Med. Chem. Lett., 2011, 21 (10), 3152-3158.
90. Testard, A.; Loge, C.; Leger, B.; Robert, J. M.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiery, V.; Besson, T. Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett., 2006, 16 (13), 3419-3423.
91. Loge, C.; Testard, A.; Thiery, V.; Lozach, O.; Blairvacq, M.; Robert, J.-M.; Meijer, L.; Besson, T. Novel 9-oxo-thiazolo[5,4-f]quinazoline-2- carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: Synthesis, biological evaluation and molecular modeling studies. Eur. J. Med. Chem., 2008, 43, 1469-1477.
92. Thaimattam, R.; Daga, P. R.; Banerjee, R.; Iqbal, J. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg. Med. Chem., 2005, 13, 4704-4712.
93. Monneret, C. Recent developments in the field of antitumour anthracyclines. Eur. J. Med. Chem., 2001, 36 (6), 483-493.
94. Binaschi, M.; Bigioni, M.; Cipollone, A.; Rossi, C.; Goso, C.; Maggi, C. A.; Capranico, G.; Animati, F. Anthracyclines: Selected new developments. Curr. Med. Chem. Anticancer Agents, 2001, 1 (2), 113-130.
95. Tewey, K. M.; Rowe, T. C.; Yang, L.; Halligan, B. D.; Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase-II. Science, 1984, 226 (4673), 466-468.
96. Kim, M. S.; Blake, M.; Baek, J. H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res., 2003, 63 (21), 7291-7300.
97. Catalano, M. G.; Fortunati, N.; Pugliese, M.; Poli, R.; Bosco, O.; Mastrocola, R.; Aragno, M.; Boccuzzi, G. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol., 2006, 191 (2), 465-472.
98. Johnson, C. A.; Padget, K.; Austin, C. A.; Turner, B. M. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J. Biol. Chem., 2001, 276 (7), 4539-4542.
99. Marchion, D. C.; Bicaku, E.; Daud, A. I.; Richon, V.; Sullivan, D. M.; Munster, P. N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamine acid. J. Cell. Biochem., 2004, 92 (2), 223-237.
100. Guerrant, W.; Patil, V.; Canzoneri, J. C.; Oyelere, A. K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J. Med. Chem., 2012, 55 (4), 1465-1477.
101. Tong, G. L.; Wu, H. Y.; Smith, T. H.; Henry, D. W. Adriamycin analogs. 3. Synthesis of N-alkylated anthracyclines with enhanced efficacy and reduced cardiotoxicity. J. Med. Chem., 1979, 22 (8), 912-918.
102. Gate, L.; Couvreur, P.; Nguyen-Ba, G.; Tapiero, H. N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells. Biomed. Pharmacother., 2003, 57 (7), 301-308.
103. Brana, M. F.; Cacho, M.; Gradillas, A.; de Pascual-Teresa, B.; Ramos, A. Intercalators as anticancer drugs. Curr. Pharm. Des., 2001, 7 (17), 1745-1780.
104. Brana, M. F.; Ramos, A. Naphthalimides as anti-cancer agents: Synthesis and biological activity. Curr. Med. Chem. Anti-Cancer Agents, 2001, 1 (3), 237-255.
105. Lv, M.; Xu, H. Overview of naphthalimide analogs as anticancer agents. Curr. Med. Chem., 2009, 16 (36), 4797-4813.
106. Antonini, I.; Santoni, G.; Lucciarini, R.; Amantini, C.; Sparapani, S.; Magnano, A. Synthesis and biological evaluation of new asymmetrical bisintercalators as potential antitumor drugs. J. Med. Chem., 2006, 49 (24), 7198-7207.
107. Van Quaquebeke, E.; Mahieu, T.; Dumont, P.; Dewelle, J.; Ribaucour, F.; Simon, G.; Sauvage, S.; Gaussin, J. F.; Tuti, J.; El Yazidi, M.; Van Vynckt, F.; Mijatovic, T.; Lefranc, F.; Darro, F.; Kiss, R. 2,2,2-Trichloro-N-({2-[2- (dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin5-yl} carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J. Med. Chem., 2007, 50 (17), 4122-4134.
108. Li, Z. G.; Yang, Q.; Qian, X. H. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: Effects of intercalation, side chains, and substituent groups. Bioorg. Med. Chem., 2005, 13 (16), 4864-4870.
109. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene, 2008, 27 (50), 6434-6451.
110. Fehrenbacher, N.; Jaattela, M. Lysosomes as targets for cancer therapy. Cancer Res., 2005, 65 (8), 2993-2995.
111. Ostenfeld, M. S.; Hoyer-Hansen, M.; Bastholm, L.; Fehrenbacher, N.; Olsen, O. D.; Groth-Pedersen, L.; Puustinen, P.; Kirkegaard-Sorensen, T.; Nylandsted, J.; Farkas, T.; Jaattela, M. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy, 2008, 4 (4), 487-499.
112. Li, W.; Yuan, X. M.; Nordgren, G.; Dalen, H.; Dubowchik, G. M.; Firestone, R. A.; Brunk, U. T. Induction of cell death by the lysosomotropic detergent MSDH. FEBS Lett., 2000, 470 (1), 35-39.
113. Groth-Pedersen, L.; Ostenfeld, M. S.; Hoyer-Hansen, M.; Nylandsted, J.; Jaattela, M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res., 2007, 67 (5), 2217-2225.
114. Chen, Z.; Liang, X.; Zhang, H. Y.; Xie, H.; Liu, J. W.; Xu, Y. F.; Zhu, W. P.; Wang, Y.; Wang, X.; Tan, S. Y.; Kuang, D.; Qian, X. H. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J. Med. Chem., 2010, 53 (6), 2589-2600.
115. Gotink, K. J.; Verheul, H. M. W. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis, 2010, 13 (1), 1-14.